Anne M. Danks, Ph.D.
Vice President, Preclinical Development
Dr. Danks is vice president of preclinical development at Autobahn Therapeutics
Dr. Danks has proven track record of successful nonclinical discovery and development of small molecule therapeutics for CNS disorders, shepherding compounds into first in human and proof of concept clinical trials. With 25 years’ experience and a focus on neurodegenerative disorders, Dr. Danks has headed small and large preclinical teams, directing all aspects of pharmacology, DMPK and toxicology, and responsible for development strategy and execution. She has guided the development of translational animal models and biomarkers to enable efficacy testing and endpoint selection in human trials. Prior to Autobahn, Dr. Danks was vice president of preclinical development at Dart NeuroScience, where she led the nonclinical development of four novel compounds enabling all phases of clinical development and conducted six additional IND-enabling programs as well as provided critical guidance and oversight for both new target and drug candidate selection. Before that, Dr. Danks was senior director of pharmacology at TorreyPines Therapeutics, where she led the preclinical and discovery in vivo pharmacology, ADME and toxicology efforts for their anti-amyloid Alzheimer’s research program. She has also held positions of increasing responsibility at Merck Research Labs, SIBIA Neurosciences, Nereus Pharmaceuticals and Cypros Pharmaceuticals. Dr. Danks completed postdoctoral training at the University of California – Irvine after receiving her Ph.D. and M.A. degrees in Psychobiology from the State University of New York at Binghamton and a B.A. degree in Psychology from Marquette University.